Overview
Treat or Refer? Improving the Management of Atopic Dermatitis in the Primary Care Setting
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Are you a puzzle enthusiast? If so, you'll love this novel educational activity that uses a clue-based crossword and word game to test your knowledge and competency in recognizing atopic dermatitis (AD). Engage with expert videos, slides, audio, and other graphical representations as you elevate your mind and advance your proficiency with AD. Conquer the CrossMED™ puzzle now!
This activity is intended for primary care providers, pediatricians, dermatologists, and others involved in the recognition or management of patients with atopic dermatitis (AD).
AD is the most common chronic inflammatory skin disease worldwide. The majority of patients, especially children, receive their initial treatment for AD in a primary care setting. Patients with mild disease may respond to initial treatment, but those with more severe disease require individualized approaches with advanced therapy options. There are also racial and ethnic variations in the presentation and severity of AD that can delay diagnosis and the initiation of therapy. Primary care providers require an understanding of how to determine whether poor adherence or incorrect medication use are factoring into the treatment of AD and when referral to a specialist may be needed.
Upon completion of this activity, learners will be able to:
- Review the prevalence, incidence, and risk factors of AD
- Discuss the differential diagnosis of AD across diverse patients
- Introduce clinical practices to ensure that patients with AD are receiving timely and optimal treatment
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Jonathan Silverberg, MD, PHD, MPH
Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Jonathan Silverberg, MD, PHD, MPH
Sources of Funding for Research: Galderma, Incyte, Pfizer
Consulting Agreements: Abbvie, Aldena, Amgen, AObiome, Arcutis, Arena, Asana, Aslan, Attovia, BioMX, Biosion, Bodewell, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, Corevitas, Dermavant, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, My-Or Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sanofi-Genzyme, Shaperon, TARGET-RWE, Union, UpToDate
Speakers’ Bureau: Abbvie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to complete the CrossMED™ puzzle, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
